Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced that it has successfully completed an eighteen month pilot program with Novartis, designed to test the ability of Horizon’s GENESISTM rAAV gene-editing platform to generate human isogenic cell lines for use by Novartis pre-clinical research programs.
16 June, 2011